|
|
|
|
|
|
|
|
|
|
|
02.09.26 - 19:33
|
A Day on the Course, A Difference in the Community: Cristo Rey Memorial Golf Outing (PR Newswire)
|
|
|
SUSSEX, Wis., Sept. 2, 2026 /PRNewswire/ -- On August 26th, Spectrum Investment Advisors proudly hosted the annual Cristo Rey Memorial Golf Outing at Ironwood Golf Course—a day filled with purpose, community, and celebration. This year, we raised $18,000, allowing us to award one......
|
|
|
26.08.26 - 15:33
|
Ironwood Warranty Group Names Wayne Davis Chief Commercial Officer (Business Wire)
|
|
|
Veteran commercial executive joins rapidly growing warranty company to lead next phase of growthLOUISVILLE, Ky.--(BUSINESS WIRE)--Ironwood Warranty Group, a leading provider of comprehensive warranty and service contract solutions, today announced the appointment of Wayne Davis as Chief Commercial Officer. In this role, Davis will lead Ironwood's commercial strategy across sales, business development, marketing, brand and strategic partnerships.
Davis joins Ironwood during a period of significant momentum. Ironwood was recently named to Louisville Business First's 2026 Fast 50, marking the fourth consecutive year the company has been recognized among the region's fastest-growing private companies.
“Ironwood has experienced tremendous growth over the past several years, and we believe we are still in the early stages of what this business can become,” said Kevin Callahan, President of Ironwood Warranty Group. “Wayne brings a rare combination of commercial leadership, brand-building expertise and e...
|
|
|
|
|
|
|
|
|
06.08.26 - 13:06
|
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results (Business Wire)
|
|
|
– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to greater than $310 million –
– Q2 2026 LINZESS U.S. net sales of $282 million; $555 million year-to-date representing 44% year-over-year growth –
– Total revenue of $113 million, GAAP net income of $51 million and adjusted EBITDA of $83 million in Q2 2026; repaid $200 million convertible notes with cash on hand –
– Confirmatory Phase 3 STARS-2 trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) now actively recruiting patients –BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance.
“Throughou...
|
|
|
30.07.26 - 22:09
|
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) using conference ID number and event passcode 3647053. To access the webcast, please visit the Investors & Media section of Ironwood's website at www.ironwoodpharma.com.
The call will be available for replay via telephone starting Thursday, August 6, 2026, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, August 20, 2026. To listen to the replay, dial (800) 770-2030 (U.S. and Canada) using conference ID number 3647053. Following the call, a replay of the webcast will be available on the Investors & Media section of the Company's website at: Ironwood Pharmaceuticals, Inc. - Events & Presentations.
About Ironwood Pharmaceut...
|
|
|
14.07.26 - 13:33
|
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients (Business Wire)
|
|
|
– Ironwood Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and Patient Care –
– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood's Next Phase of R&D Strategy and Execution –BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey Silber as his successor. Dr. Silber will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs reporting to Chief Executive Officer Tom McCourt. Dr. Silber joins Ironwood on July 20, 2026 and Dr. Shetzline will remain an advisor to the company to ensure a seamless transition. The company also announced today that the confirmatory Phase 3 ST...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
